Articles related to MIGRAINES

Misunderstandings and misperceptions about migraine persist, leading to misdiagnosis and less-than-optimal management. In this video, migraine experts seek to update the primary care provider on the current understanding of the disease, and the role of gepants, ditans, triptans, calcitonin gene-related peptide antibodies, and other therapies.

This broad review of recent studies in women’s health topics aims to help the primary care physician in discussing and guiding therapy for women in topics from cardiovascular disease to pelvic pain. The review covers such questions as: How does migraine with aura affect CVD risk in women? How do you respond to patient questions about fracture risk and bisphosphonates? Are antidepressants safe for women who are considering pregnancy? Is gabapentin effective for chronic pelvic pain?

A total of 35 status migrainosus patients were enrolled; 30 of them were female, and the average age was 39. Before the drugs were given, everyone’s serum magnesium levels were normal. There were no ECG alterations found, and none of the patients experienced any severe side effects either during or right away following the infusion. In 15 patients, there was a positive effect; in 10, there was no effect; and in 10, there were no data.

Few classes of therapeutics have been specifically developed to combat migraine, despite its global impact on disability. However, after 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine.

The research shows that chronic pain, inflammatory bowel disease, cancer, and migraines all play a role in the development of mental diseases. Healthcare practitioners should take a careful history and keep in mind comorbidities when treating patients for any of these conditions.